Another drug proposed for the MCL(e)toMCL transition is regorafenib, an inhibitor of multiple kinases administered in metastatic colorectal cancer patients that have previously received anti-VEGF therapy [40], metastatic gastrointestinal stromal tumor that have been treated with imatinib [41] and hepatocellular carcinoma. This evidence concerns the gene VEGFA and hepatocellular carcinoma.